Aims: Current recommendations on the use of bivalirudin in patients treated with
percutaneous coronary intervention (PCI) are mostly based on trials comparing bivalirudin …

Background Bivalirudin is an alternative to heparin in patients undergoing percutaneous
coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based …

Bivalirudin is an alternative to unfractionated heparin (UFH) anticoagulation during
percutaneous coronary intervention. Previously, we have reported clinical benefit on major …

Introduction: Bivalirudin and heparin are the two most commonly used anticoagulants used
during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled …

Background Bivalirudin significantly reduces 30-day major and minor bleeding compared
with unfractionated heparin (UFH), while resulting in similar or lower rates of ischemic …

Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa
inhibitors has been shown to be as effective as unfractionated heparin plus routine …

Objective: This study evaluates outcomes with bivalirudin vs heparin in various patient
subgroups and the overall population during percutaneous coronary interventions (PCI) …

Objective. To compare clinical outcomes and glycoprotein IIb‐IIIa inhibitor use in patients
undergoing percutaneous coronary intervention (PCI) who received bivalirudin or …

Background The comparative efficacy of various anticoagulation strategies has not been
clearly established in patients with acute myocardial infarction who are undergoing …

Background Bivalirudin has been shown to be associated with less major bleeding than
heparin in patients undergoing percutaneous coronary intervention (PCI); but the …